Adaptive Biotechnologies raises $250M in convertible notes, plans MRD spinoff

What's the deal? Adaptive Biotechnologies has completed a $250M private offering of unsecured, senior, callable convertible notes due July 1, 2031. Alongside the fundraise, the company is planning to separate its profitable Minimal Residual Disease (MRD) unit from its Immune Medicine business.

Proceeds will go toward repaying existing obligations, funding capped call transactions, repurchasing up to $25M of stock, and general corporate purposes tied to MRD.

Why now? Adaptive has raised its 2026 MRD revenue guidance and reports a growing pharma trial backlog for the division. The separation lets investors evaluate MRD — the company's strongest asset — on its own merits, while Immune Medicine pursues growth under a structure better suited to its earlier-stage profile.

Analysts project Adaptive could reach $451.6M in revenue and $70.4M in earnings by 2029, which would require roughly 15.2% annual revenue growth and a swing of about $120M from current losses of $49.7M.

What could go wrong? Adaptive remains unprofitable company-wide. If losses persist and cash needs grow, further dilution or cost cuts could follow — the very outcome the convertible notes are meant to forestall.

The convertible structure itself carries dilution risk if the notes eventually convert to equity. And betting the company's future on MRD as the sole engine means any slowdown in that business would hit especially hard once the Immune Medicine unit is separated.

The signal: Adaptive's move to carve out its profitable MRD division mirrors a growing playbook among late-stage life sciences companies: isolate the revenue engine, give it a standalone valuation, and use structured debt to bridge the gap rather than tapping equity markets at a discount. With community fair value estimates ranging from $20.14 to $22 per share — implying up to 28% upside — the bet is that a cleaner corporate structure will close the gap between Adaptive's current losses and MRD's growth trajectory before the 2031 notes mature.

Read more: Simply Wall St

Image: Adaptive Biotechnologies' Seattle building, by Joe Mabel (CC BY-SA 4.0)